Enter your keywords

Insulin aspart Sanofi (Trurapi): Biosimilar Insulin Aspart

Overview Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing. Insulin aspart Sanofi (Trurapi®▼) is the first biosimilar of insulin aspart (NovoRapid®). It is licensed for the treatment of diabetes […]

Omalizumab and dupilumab for chronic rhinosinusitis with nasal polyps

Overview Evaluation reports aim to give objective information and guidance on medicines and medical devices to commissioners of health services, prescribers and others. They include efficacy, adverse effects, place in treatment and arrangements for prescribing. Omalizumab and dupilumab are indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe chronic […]

Solriamfetol for obstructive sleep apnoea

Solriamfetol is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). This publication reviews its efficacy and safety, and the limitations of the evidence. Solriamfetol is also licensed […]

Solriamfetol for narcolepsy

Solriamfetol is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with narcolepsy with or without cataplexy. This publication reviews its efficacy and safety, and the limitations of the evidence. Solriamfetol is also licensed to improve wakefulness and reduce EDS in adults with obstructive sleep apnoea (see separate RDTC evaluation).

ActiPatch for the management of localised musculoskeletal pain

ActiPatch® (BioElectronics) is a wearable pulsed shortwave therapy device for the management of localised musculoskeletal pain (sometimes referred to as pulsed electromagnetic field therapy – PEMF). The device is placed directly over the source of pain and held in place with wraps, adhesives, bandages or clothing, and can be used for up to 24 hours […]

Naloxone nasal spray for opioid overdose

Naloxone 1.8 mg nasal spray (Nyxoid®, Mundipharma) is a single dose solution licensed in adults and adolescents aged 14 years and over. It is indicated for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both nonmedical and healthcare settings.